



# Biotech Daily

Wednesday August 27, 2025

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: ATOMO UP 11%; AMPLIA DOWN 10.5%**
- \* **NEUREN H1 REVENUE UP 24% TO \$39.7m; PROFIT UP 88% TO \$15m**
- \* **COMPUMEDICS REVENUE UP 2.5% TO \$51m; LOSS UP 155% TO \$1.3m**
- \* **MACH7 REVENUE UP 16% TO \$34m; LOSS DOWN 22% TO \$6m**
- \* **AUDEARA REVENUE UP 19% TO \$3.8m; LOSS UP 11% TO \$2m**
- \* **OPTISCAN \$17.75m RIGHTS OFFER**
- \* **PATRY'S UNDERWRITTEN RIGHTS RAISE \$1.8m**
- \* **CLEVER CULTURE 55mm APAS CONTACT PLATE MODULE**
- \* **BCAL, SONIC HEALTHCARE BREASTEST PLUS DEAL**
- \* **NEUROSCIENTIFIC: DATA BACKS STEMSMART FOR RENAL TRANSPLANTS**
- \* **CARTHERICS CHINA STEM CELL PATENT**
- \* **GOODBYE OPYL, HELLO PATHKEY.AI**
- \* **AMPLIA AGM 26% OPPOSE SHARE PLAN**
- \* **BIOXYNE FILES LEGAL SUMMONS AGAINST 7% INVESTOR IAN OWLES**
- \* **RHYTHM CHAIR OTTO BUTTULA DILUTED TO 11%**
- \* **FIL (FIDELITY) INCREASES, DILUTED TO 8.8% OF CYNATA**
- \* **ARTRYA EX-M-D JOHN BARRINGTON INCREASES, DILUTED TO 6.4%**

## MARKET REPORT

The Australian stock market was up 0.28 percent on Wednesday August 27, 2025, with the ASX200 up 24.9 points to 8,960.5 points. Sixteen of the Biotech Daily Top 40 stocks were up, 14 fell, eight traded unchanged and two were untraded.

Atomo was best, up 0.2 cents or 11.1 percent to two cents, with 8.2 million shares traded. Optiscan was up 10 percent; Curvebeam climbed 7.1 percent; Neuren and Polynovo were up more than six percent; Alcidion improved five percent; Aroa, Cynata and Starpharma were up more four percent or more; Imugene was up 3.85 percent; EBR rose 2.2 percent; Dimerix, Mesoblast, Pro Medicus, SDI and Syntara were up more than one percent; with Cochlear, CSL and Orthocell up by less than one percent.

Amplia led the falls, down two cents or 10.5 percent to 17 cents, with 8.3 million shares traded. Actinogen lost 9.4 percent; 4D Medical shed 6.4 percent; Nanosonics was down 5.5 percent; Resonance fell 4.65 percent; Botanix was down 3.1 percent; Immutep, Impedimed, Medical Developments and Telix shed two percent or more; Avita, Clarity and Clinuvel were down more than one percent; with Cyclopharm and Resmed down by less than one percent.

## NEUREN PHARMACEUTICALS

Neuren says revenue for the six months to June 30, 2025 was up 23.7 percent to \$39,723,000, with net profit after tax up 87.5 percent to \$15,031,000.

Neuren said revenue was from royalties on sales of its trofenitide for Rett syndrome, marketed by Acadia Pharmaceuticals as Daybue in the US, as well as finance income and net foreign currency gains (BD: Mar 13, Jun 7, 2023).

The company said Acadia net Daybue sales were up 12.6 percent to \$US180.7 million (\$A278.2 million) for the six months, with full-year sales expected to be between \$US380 million and \$US405 million, resulting in royalty income of between \$62 million and \$67 million compared to \$56 million in the prior corresponding period.

Neuren said it had a \$17,969,000 loss incurred from foreign currency translation.

The company said research and development costs were down 16.7 percent to \$14,897,000, with corporate and administrative costs up 4.6 percent to \$2,483,000 and it had a loss on financial derivatives of \$2,622,000.

Neuren said that diluted earnings per share rose 90.0 percent to 11.65 cents, with net tangible assets per share down 9.4 percent to \$2.4787 and it had cash and equivalents of \$5,906,000 at June 30, 2025, compared to \$2,571,000 at June 30, 2024.

Neuren was up \$1.20 or 6.7 percent to \$19.00 with 944,206 shares traded.

## COMPUMEDICS

Compumedics says revenue for the year to June 30, 2025 was up 2.5 percent to a record \$50,957,000, with net loss after tax up 154.9 percent to \$1,272,000.

Compumedics said revenue was from sales of its Somfit and Nexus360 sleep diagnostics, Okti wireless amplifier, ultrasonic blood-flow systems, supplies and support services, with net sales orders up 22 percent to a record \$63.4 million.

The company said no revenue was recognized for its magneto-encephalogram (MEG) system for brain mapping compared to \$4.7 million in the previous year, with two four-year distribution agreements in China signed totaling \$24.4 million and all three MEG orders expected to be recognized in 2025-'26.

Compumedics said it expected revenue of more than \$70 million in the year to June 30, 2026 due to expansion of Somfit and Nexus360 software sales, delivery of MEG orders in China and continued US commercialization of its sleep and brain diagnostics.

The company said diluted loss per share was up 250 percent to 0.7 cents, with net tangible asset backing per share down 40.0 percent to 2.7 cents and it had cash of \$2,690,000 at June 30, 2025 compared to \$1,890,000 at June 30, 2024.

Compumedics was unchanged at 28.5 cents.

## MACH7 TECHNOLOGIES

Mach7 says its revenue for the year to June 30, 2025 was up 16.0 percent to \$33,768,195, with net loss after tax down 22.2 percent to \$6,201,404.

Mach7 said its increased revenue from subscriptions, maintenance and support, and licencing its Enterprise imaging software, diagnostic viewing and workflow applications and data management systems reflected "strong growth in high quality recurring revenue, which represented 75 percent of total revenue".

The company said diluted loss per share fell 21.2 percent to 2.6 cents, with net tangible assets per share down two percent to 9.8 cents and it had cash of \$23,069,049 at June 30, 2025 compared to \$26,175,405 at June 30, 2024.

Mach7 fell 2.5 cents or 7.35 percent to 31.5 cents.

### [AUDEARA](#)

Audeara says revenue for the year to June 30, 2025 was up 18.6 percent to \$3,785,788, with net loss after tax up 11.5 percent to \$1,787,038.

Audeara said revenue was from the sale of its hearing aid products as well as engineering services and manufacturing services of audio devices.

The company said it would focus on delivering orders from Avedis Zildjian, as well as continuing to strengthen relationships and other wholesale agreements (BD: Feb 5, 2025).

Audeara said diluted loss per share fell 1.8 percent to 1.09 cents, net tangible assets per share was down 37.3 percent to 0.69 cents and it had cash and cash equivalents of \$1,421,091 at June 30, 2025 compared to \$1,271,800 at June 30, 2024.

Audeara fell 0.1 cents or 3.85 percent to 2.5 cents.

### [OPTISCAN IMAGING](#)

Optiscan says it expects to raise \$17,750,992 at 8.5 cents a share in a one-for-four entitlement offer, fully-underwritten by shareholder Peters Investments Pty Ltd.

Biotech Daily calculates the price is a 6.25 percent premium to the last closing price.

Optiscan said the funds would be for clinical studies, testing and certification of its Invue, Inform and Inspecta clinical microscopes and devices as well as filing for US clearance.

The company said Peters Investments had agreed to take up its full entitlement of \$5,011,615, as well as fully-underwrite any shortfall under offer.

Optiscan said Canaccord Genuity Australia was managing the rights issue.

The company said the offer had a record date of September 2, would open on September 5 and close on September 16, 2025.

Optiscan was up 0.8 cents or 10 percent to 8.8 cents.

### [PATRYS](#)

Patrys says it has raised \$423,479 at 0.1 cents a share in a fully-underwritten rights offer, with the remaining \$1,350,878 shortfall placed to the underwriter.

In July, Patrys said it expected to raise \$1,774,357 at 0.1 cents a share, in a one-for-four, fully-underwritten entitlement offer, with one attaching share for every four shares issued, saying the structure made the "effective cost" 0.08 cents a share (BD: Jul 24, 2025).

Today, Patrys said Templar Corporate Pty Ltd was the underwriter of the rights issue.

Patrys was untraded at 0.15 cents.

### [CLEVER CULTURE SYSTEMS \(FORMERLY LBT INNOVATIONS\)](#)

Clever Culture says it has validated the automated plate assessment system (Apas) analysis module for 55mm contact plates, with the technology available for sale.

Last year, Clever Culture said it was developing a module for Apas to read 55mm contact plates for pharmaceutical environmental monitoring, with "several customers" expressing interest in the technology.

The then LBT said pharmaceutical businesses used 90mm settle plates for air monitoring and smaller 55mm contact culture plates for surfaces and personnel.

Today, the company said the addition of a contact plate application to the Apas

Independence offered "a single technology platform capable of covering the vast majority of environmental monitoring tests performed".

Clever Culture fell 0.1 cents or 2.9 percent to 3.4 cents with seven million shares traded.

### BCAL DIAGNOSTICS

Bcal says Sonic Healthcare Australia Pathology Ptd Ltd will sell its Breastest Plus non-invasive breast cancer blood test at its 93 pathology centres in Sydney.

Earlier this year, Bcal said its Breastest Plus breast cancer blood test would be sold at Sydney Breast Clinic, with a planned roll-out of Breastest Plus at additional clinical sites, initially in Melbourne and Sydney, to follow (BD: Mar 24, 2025).

Today, the company said it continued to progress commercialization of Breastest, with "further expansion planned in the coming months".

Bcal chief executive officer Shane Ryan said the deal with Sonic Healthcare Australia was "an important milestone in Bcal's commercial roll-out".

"By partnering with Sonic, we are making it convenient for women to have the Breastest Plus blood test taken close to home helping both patients and clinicians alike," Mr Ryan said.

"Quicker access to clinic and faster turnaround times aids better detection of disease and its management," Mr Ryan said.

Bcal was up 0.7 cents or 12.5 percent to 6.3 cents.

### NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific says 2015 and 2017 studies support the use of its acquired Stemsmart mesenchymal stromal cells for use in renal disease-related kidney transplants.

Earlier this year, Neuroscientific said it completed its acquisition of Perth's Isopogen WA and its Stemsmart technology for scrip (BD: Jun 27, 2025).

At that time, the company said it had begun a special access program of the Stemsmart mesenchymal stem cells for fistulizing Crohn's disease.

Today, Neuroscientific said eight of 10 patients in a special access scheme conducted between 2012 and 2015 had renal function stabilized and T-cell and inflammatory cell reduction confirmed with biopsy after mesenchymal stromal cell treatment.

The company said a separate 12-patient, phase I trial conducted between 2014 and 2017 showed mesenchymal stromal cells were administered in theatre and on the ward without complication, with treatment well-tolerated.

Neuroscientific said the phase I trial showed no infectious complications, two patients had delayed graft function and compared to 114 deceased-donor controls there was a trend to better initial graft function at one and three months with Stemsmart treatment.

The company said kidney function at three and 12 months "was excellent in all 12 subjects", with two patients treated for rejection within six months of transplant.

Neuroscientific said the studies supported further clinical development and the potential of Stemsmart for preventing and treating graft failure and rejection.

Neuroscientific fell half a cent or three percent to 16 cents.

### CARTHERICS PTY LTD

Cartherics says the Chinese Patent Office has granted a patent protecting its induced pluripotent stem cells (IPSC) for solid tumors.

Cartherics said the patent, titled 'Method for Providing Immune Cells with Enhanced Function' would protect its intellectual property until November 2040.

The company said the patent covered its IPSC-derived natural killer (NK) cells "engineered to knock-out the adenosine A2A receptor (A2AR) -0 a receptor known to suppress immune function in the tumor micro-environment".

Cartherics is a private company.

### OPYL (TO BE PATHKEY.AI; FORMERLY SHAREROOT)

Opyl says it will formally change its name to Pathkey.AI tomorrow and begin trading on the ASX under the ticker code 'PKY'.

Last month, Opyl said its extraordinary general meeting voted 98.70 percent in favor of its change of company name to 'Pathkey.AI' (BD: Jul 25, 2025).

In 2019, a then Shareroot annual general meeting changed the company's name to Opyl (BD: Nov 27, 2019)

Opyl was up 0.2 cents or 9.1 percent to 2.4 cents.

### AMPLIA THERAPEUTICS

Amplia says its annual general meeting passed all resolutions with up-to 26.3 percent opposing the issue of share plan shares and shortfall offer.

In July, Amplia said it raised \$25 million at 23 cents a share, with a fully-underwritten, \$2.5 million share plan to follow at the lower of the placement price of 23 cents a share and a 5.0 percent discount to the 5-day volume weighted average price; and last week, Amplia said the plan raised \$2.65 million at 18 cents a share (BD: Jul 23, Aug 26, 2025).

Today, the company said the share purchase plan and shortfall offer was opposed by 36,676,052 votes (26.26%), with 103,008,717 votes (73.74%) in favor.

Amplia said the 10 percent placement facility was opposed by 38,183,052 votes (22.87%) and the remaining resolutions were all passed with overwhelming support.

According to its most recent filing, Amplia had 486,477,023 shares on issue, meaning that the 38,183,052 votes against the 10% placement facility amounted to 7.85 percent of the company, sufficient to requisition extraordinary general meetings.

Amplia fell two cents or 10.5 percent to 17 cents with 8.3 million shares traded.

### BIOXYNE

Bioxyne says it has filed a summons against substantial shareholder Ian Owles in the Supreme Court of New South Wales.

Bioxyne said the claim sought "relief pursuant to sections 236 and 237 of the Australian Consumer Law (NSW) arising from misrepresentations made by Mr Owles which lead [sic] to the issue of shares to him in Bioxyne".

In 2023, Mr Owles said he became a substantial shareholder in Bioxyne, with 132,488,966 shares, or 6.97 percent of the company, acquiring the shares in consideration for the sale of shares in Breathe Life Sciences (BD: Jun 1, 2023).

Today, the company said it claimed "relief for loss and damage, or in the alternative, that the shares issued to Mr Owles be declared void ab-initio or that he is not entitled to enforce his rights in respect of the shares".

Bioxyne said the summons had no impact on its operations.

Bioxyne was up 0.1 cents or 1.75 percent to 5.8 cents with 11.4 million shares traded.

### RHYTHM BIOSCIENCES

Rhythm chair Otto Buttula says his 36,384,575 share-holding in the company has been diluted from 12.83 percent to 11.29 percent due to a placement on August 22, 2025.

Last week, Rhythm said it expected to raise \$3.75 million at 9.0 cents a share in a placement, with one option for each new share, exercisable at 20 cents each by November 30, 2027 (BD: Aug 18, 2025).

Rhythm was up 0.2 cents or two percent to 10 cents.

### CYNATA THERAPEUTICS

FIL Limited (Fidelity Investment Management) says it has increased and been diluted in Cynata from 9,506,625 shares (10.00%) to 20,967,806 shares (8.83%).

The Hong Kong-based FIL said between July 2, 2018 and December 10, 2024 it bought shares at prices ranging from 18 cents to \$1.6019 a share and sold shares at prices ranging from 67 cents to \$1.40 a share.

Last week, Cynata said it had an up-to \$7,500,000, five-year at-the-market (ATM) subscription agreement from Sydney's Acuity Capital (BD: Aug 22, 2025).

At that time, the company said Acuity Capital was "not obliged to subscribe for shares if or when requested by Cynata", and that it had agreed to place 11,500,000 shares from its Listing Rule 7.1 capacity at no cash consideration to Acuity Capital as security.

Cynata was up one cent or 4.9 percent to 21.5 cents.

### ARTRYA

Artrya co-founder and former managing-director John Barrington says he increased his holding and was diluted from 6,933,146 shares (7.65%) to 7,475,253 shares (6.42%).

The Perth-based Mr Barrington said that on August 22, 2025 he sold 357,893 shares for \$721,369, or \$2.02 a share and on August 25, 2025 sold a further 100,000 shares for \$197,854, or \$1.98 a share and acquired 1,000,000 shares through the exercise of options for \$1,000,000, or \$1.00 each.

Earlier this year, Artrya said it had "commitments" to raise \$15 million at 73 cents a share in a placement to fund its Salix coronary software (BD: Feb 14, 2025).

Artrya was up three cents or 1.5 percent to \$2.04.